MX2009012188A - Métodos de tratamiento y prevención de enfermedades y desórdenes neurodegenerativos. - Google Patents
Métodos de tratamiento y prevención de enfermedades y desórdenes neurodegenerativos.Info
- Publication number
- MX2009012188A MX2009012188A MX2009012188A MX2009012188A MX2009012188A MX 2009012188 A MX2009012188 A MX 2009012188A MX 2009012188 A MX2009012188 A MX 2009012188A MX 2009012188 A MX2009012188 A MX 2009012188A MX 2009012188 A MX2009012188 A MX 2009012188A
- Authority
- MX
- Mexico
- Prior art keywords
- disease
- methods
- disorders
- neurodegenerative diseases
- prevention
- Prior art date
Links
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 3
- 230000004770 neurodegeneration Effects 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title 1
- 230000008499 blood brain barrier function Effects 0.000 abstract 3
- 210000001218 blood-brain barrier Anatomy 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 102000016752 1-Alkyl-2-acetylglycerophosphocholine Esterase Human genes 0.000 abstract 1
- 108010024976 Asparaginase Proteins 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 201000004810 Vascular dementia Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
- C12N9/20—Triglyceride splitting, e.g. by means of lipase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Psychology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Psychiatry (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2007/011365 WO2008140449A1 (en) | 2007-05-11 | 2007-05-11 | Methods of treatment and prevention of neurodegenerative diseases and disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009012188A true MX2009012188A (es) | 2010-02-24 |
Family
ID=40002489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009012188A MX2009012188A (es) | 2007-05-11 | 2007-05-11 | Métodos de tratamiento y prevención de enfermedades y desórdenes neurodegenerativos. |
Country Status (10)
| Country | Link |
|---|---|
| EP (2) | EP2977452A3 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5277243B2 (cg-RX-API-DMAC7.html) |
| KR (3) | KR101690390B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN101986785A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2007353454C8 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0721697A2 (cg-RX-API-DMAC7.html) |
| EA (1) | EA200971050A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2540933T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2009012188A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008140449A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2651403B1 (en) * | 2010-12-17 | 2020-12-02 | Glaxo Group Limited | Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases |
| US9227953B2 (en) | 2011-09-01 | 2016-01-05 | Glaxo Group Limited | Crystal form |
| WO2013070079A2 (en) * | 2011-11-10 | 2013-05-16 | Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk, | miRNA IN BLOOD BRAIN BARRIER OF MS PATIENTS |
| MX379251B (es) | 2012-04-02 | 2025-03-11 | Genomatica Inc | Producción mejorada de derivados de ácidos grasos. |
| EP2764866A1 (en) | 2013-02-07 | 2014-08-13 | IP Gesellschaft für Management mbH | Inhibitors of nedd8-activating enzyme |
| KR101523841B1 (ko) * | 2013-09-05 | 2015-05-28 | 건국대학교 산학협력단 | Nadph 산화효소 1의 억제제를 유효성분으로 포함하는 혈관성 치매의 치료 또는 예방용 조성물 |
| WO2016012916A1 (en) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
| WO2016012917A1 (en) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
| US20190092789A1 (en) * | 2015-09-04 | 2019-03-28 | Lysosomal Therapeutics Inc. | Heterobicyclic pyrimidinone compounds and their use in the treatment of medical disorders |
| CN105177013A (zh) * | 2015-10-25 | 2015-12-23 | 李蒙 | 一种用于检测脑血管疾病的试剂盒 |
| US11793782B2 (en) * | 2017-10-18 | 2023-10-24 | Intrabio Limited | Therapeutic agents for neurodegenerative diseases |
| EP3806956A4 (en) * | 2018-06-13 | 2022-08-10 | Zachriel Neurosciences, Llc | METHODS AND DOSAGE REGIMES FOR PREVENTING OR DELAYING THE ONSET OF ALZHEIMER'S DISEASE AND OTHER FORMS OF DEMENTIA AND MILD COGNITIVE IMPAIRMENT |
| US20210332363A1 (en) * | 2018-08-30 | 2021-10-28 | NEXMOS Co.,Ltd | Blood-brain barrier permeable aptamer and application thereof |
| JP7584766B2 (ja) * | 2019-01-09 | 2024-11-18 | 健一 山田 | 脳血管障害および認知症の治療のための医薬組成物 |
| CN111825695B (zh) * | 2019-04-15 | 2022-04-12 | 中国科学院上海药物研究所 | 噁唑烷酮类化合物、其制备方法、用途及其药物组合物 |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4309406A (en) | 1979-07-10 | 1982-01-05 | American Home Products Corporation | Sustained release pharmaceutical compositions |
| US4309404A (en) | 1979-08-09 | 1982-01-05 | American Home Products Corporation | Sustained release pharmaceutical compositions |
| US4556552A (en) | 1983-09-19 | 1985-12-03 | Colorcon, Inc. | Enteric film-coating compositions |
| US4704295A (en) | 1983-09-19 | 1987-11-03 | Colorcon, Inc. | Enteric film-coating compositions |
| IL73883A (en) | 1984-12-20 | 1990-12-23 | Yeda Res & Dev | Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha |
| US5235033A (en) | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US4666829A (en) | 1985-05-15 | 1987-05-19 | University Of California | Polypeptide marker for Alzheimer's disease and its use for diagnosis |
| US5580774A (en) | 1989-07-31 | 1996-12-03 | Eli Lilly And Company | Chimeric antibodies directed against a human glycoprotein antigen |
| WO1991006556A1 (en) | 1989-10-24 | 1991-05-16 | Gilead Sciences, Inc. | 2' modified oligonucleotides |
| SG88714A1 (en) | 1989-11-06 | 2002-05-21 | Cell Genesys Inc | Production of proteins using homologous recombination |
| DE779362T1 (de) | 1989-12-22 | 2001-04-05 | Applied Research Systems Ars Holding N.V., Curacao | DNS-Konstrukten zur Aktivierung und Veränderung der Expression von endogenen Genen |
| US5272071A (en) | 1989-12-22 | 1993-12-21 | Applied Research Systems Ars Holding N.V. | Method for the modification of the expression characteristics of an endogenous gene of a given cell line |
| US5223618A (en) | 1990-08-13 | 1993-06-29 | Isis Pharmaceuticals, Inc. | 4'-desmethyl nucleoside analog compounds |
| US5610289A (en) | 1990-07-27 | 1997-03-11 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogues |
| JPH0874B2 (ja) | 1990-07-27 | 1996-01-10 | アイシス・ファーマシューティカルス・インコーポレーテッド | 遺伝子発現を検出および変調するヌクレアーゼ耐性、ピリミジン修飾オリゴヌクレオチド |
| US5623070A (en) | 1990-07-27 | 1997-04-22 | Isis Pharmaceuticals, Inc. | Heteroatomic oligonucleoside linkages |
| US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
| US5602240A (en) | 1990-07-27 | 1997-02-11 | Ciba Geigy Ag. | Backbone modified oligonucleotide analogs |
| US5177196A (en) | 1990-08-16 | 1993-01-05 | Microprobe Corporation | Oligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof |
| AU652997B2 (en) | 1991-01-21 | 1994-09-15 | Elan Pharmaceuticals, Inc. | Test and model for alzheimer's disease |
| US5672697A (en) | 1991-02-08 | 1997-09-30 | Gilead Sciences, Inc. | Nucleoside 5'-methylene phosphonates |
| DE07012626T1 (de) | 1991-03-18 | 2010-01-21 | New York University | Monoklonale und chimäre Antikörper gegen humanen Tumornekrosefaktor |
| AU664847B2 (en) | 1991-05-15 | 1995-12-07 | Cell Genesys, Inc. | Genomic modifications with homologous DNA targeting |
| NZ245015A (en) | 1991-11-05 | 1995-12-21 | Transkaryotic Therapies Inc | Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production |
| CA2142300C (en) | 1992-10-13 | 2005-08-23 | Allen D. Roses | Methods for detecting alzheimer's disease |
| TW402639B (en) | 1992-12-03 | 2000-08-21 | Transkaryotic Therapies Inc | Protein production and protein delivery |
| US5858988A (en) | 1993-02-24 | 1999-01-12 | Wang; Jui H. | Poly-substituted-phenyl-oligoribo nucleotides having enhanced stability and membrane permeability and methods of use |
| WO1995000649A1 (en) | 1993-06-25 | 1995-01-05 | Smithkline Beecham Plc | Lipoprotein associated phospholipase a2, inhibitors thereof and use of the same in diagnosis and therapy |
| EP1096016B1 (en) | 1993-10-06 | 2006-01-11 | Icos Corporation | Platelet-activating factor acetylhydrolase |
| US5519134A (en) | 1994-01-11 | 1996-05-21 | Isis Pharmaceuticals, Inc. | Pyrrolidine-containing monomers and oligomers |
| GB9421816D0 (en) | 1994-10-29 | 1994-12-14 | Smithkline Beecham Plc | Novel compounds |
| WO1996019451A1 (en) | 1994-12-22 | 1996-06-27 | Smithkline Beecham Plc | Substituted azetidin-2-ones for treatment of atherosclerosis |
| HUP9901153A3 (en) | 1995-07-01 | 1999-11-29 | Smithkline Beecham Plc | Azetidinone derivatives for the treatment of atherosclerosis, their production and pharmaceutical compositions containing them |
| US5705629A (en) | 1995-10-20 | 1998-01-06 | Hybridon, Inc. | Methods for H-phosphonate synthesis of mono- and oligonucleotides |
| EP0865429A1 (en) * | 1995-12-08 | 1998-09-23 | Smithkline Beecham Plc | Azetidinone compounds for the treatment of atherosclerosis |
| EP0869943A1 (en) | 1995-12-08 | 1998-10-14 | Smithkline Beecham Plc | Monocyclic beta-lactame derivatives for treatment of atherosclerosis |
| GB9608649D0 (en) | 1996-04-26 | 1996-07-03 | Smithkline Beecham Plc | Novel compounds |
| CZ341098A3 (cs) | 1996-04-26 | 1999-03-17 | Smithkline Beecham Plc | Azetidinonové deriváty pro ošetřování aterosklerózy |
| WO1999024420A1 (en) | 1997-11-06 | 1999-05-20 | Smithkline Beecham Plc | Pyrimidinone compounds and pharmaceutical compositions containing them |
| US6913745B1 (en) | 1997-12-02 | 2005-07-05 | Neuralab Limited | Passive immunization of Alzheimer's disease |
| US6787523B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| DE69911980T2 (de) | 1998-08-21 | 2004-09-09 | Smithkline Beecham P.L.C., Brentford | Pyrimidinonderivate zur behandlung von atheroscleros |
| GB9910079D0 (en) | 1999-05-01 | 1999-06-30 | Smithkline Beecham Plc | Novel compounds |
| DE60042286D1 (de) | 1999-05-01 | 2009-07-09 | Smithkline Beecham Plc | Pyrimidinon Verbindungen |
| GB9910378D0 (en) | 1999-05-05 | 1999-06-30 | Smithkline Beecham Plc | Novel compounds |
| DE60139429D1 (de) | 2000-02-16 | 2009-09-10 | Smithkline Beecham Plc | Pyrimidin-5-Onderivate als LDL-PLA2 Inhibitoren |
| JP2003526367A (ja) | 2000-03-16 | 2003-09-09 | ジェネティカ インコーポレイテッド | Rna干渉の方法とrna干渉組成物 |
| WO2007028133A2 (en) | 2005-08-30 | 2007-03-08 | Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Treatment and prevention of vascular dementia |
| US7107092B2 (en) | 2000-08-21 | 2006-09-12 | The General Hospital Corporation | Methods for diagnosing a neurodegenerative condition |
| GB0024807D0 (en) | 2000-10-10 | 2000-11-22 | Smithkline Beecham Plc | Novel compounds |
| GB0024808D0 (en) | 2000-10-10 | 2000-11-22 | Smithkline Beecham Plc | Novel compounds |
| AU2002248224B2 (en) | 2000-10-27 | 2006-11-09 | Baylor College Of Medicine | Methods and compositions for the identification and treatment of neurodegenerative disorders |
| US6884591B2 (en) | 2001-06-25 | 2005-04-26 | The Cleveland Clinic Foundation | Peripheral marker of blood brain barrier permeability |
| GB0119793D0 (en) * | 2001-08-14 | 2001-10-03 | Smithkline Beecham Plc | Novel compounds |
| GB0119795D0 (en) | 2001-08-14 | 2001-10-03 | Smithkline Beecham Plc | Novel process |
| GB0127140D0 (en) * | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Novel compounds |
| GB0127143D0 (en) | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Novel compounds |
| GB0127139D0 (en) | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Novel compounds |
| GB0127141D0 (en) | 2001-11-10 | 2002-01-02 | Smithkline Beecham Plc | Novel compounds |
| GB0208279D0 (en) | 2002-04-10 | 2002-05-22 | Glaxo Group Ltd | Novel compounds |
| GB0208280D0 (en) | 2002-04-10 | 2002-05-22 | Glaxo Group Ltd | Novel compounds |
| AU2003248660A1 (en) | 2002-06-11 | 2003-12-22 | Socratech, L.L.C. | Treatment of vascular dysfunction and alzheimer's disease |
| US20060241130A1 (en) * | 2003-01-31 | 2006-10-26 | Ehud Keinan | Anti-inflammatory compositions and uses thereof |
| CA2435538A1 (en) | 2003-07-18 | 2005-01-18 | Universite Laval | Solvent resistant asymmetric integrally skinned membranes |
| GB0320522D0 (en) | 2003-09-02 | 2003-10-01 | Glaxo Group Ltd | Formulation |
| US20050108779A1 (en) | 2003-10-21 | 2005-05-19 | Envivo Pharmaceuticals, Inc. | Transgenic flies expressing Abeta42-Italian |
| US20040255342A1 (en) | 2003-10-21 | 2004-12-16 | Envivo Pharmaceuticals, Inc. | Transgenic flies expressing Abeta42-Iowa |
| US20040250302A1 (en) | 2003-10-21 | 2004-12-09 | Envivo Pharmaceuticals, Inc. | Transgenic flies expressing Abeta42-dutch |
| US20040244064A1 (en) | 2003-10-20 | 2004-12-02 | Envivo Pharmaceuticals, Inc. | Transgenic flies expressing Abeta42-Flemish |
| US20050132423A1 (en) | 2003-10-20 | 2005-06-16 | Envivo Pharmaceuticals, Inc. | Transgenic flies expressing Abeta42-Flemish |
| US20040255341A1 (en) | 2003-10-21 | 2004-12-16 | Envivo Pharmaceuticals, Inc. | Transgenic flies expressing Abeta42-Arctic |
| US20050132424A1 (en) | 2003-10-21 | 2005-06-16 | Envivo Pharmaceuticals, Inc. | Transgenic flies expressing Abeta42-Dutch |
| US20050132421A1 (en) | 2003-10-21 | 2005-06-16 | Envivo Pharmaceuticals, Inc. | Transgenic flies expressing Abeta42-Arctic |
| US20050132422A1 (en) | 2003-10-21 | 2005-06-16 | Envivo Pharmaceuticals, Inc. | Transgenic flies expressing Abeta42-Iowa |
| KR100784337B1 (ko) | 2004-11-12 | 2007-12-13 | 한국생명공학연구원 | 신규한 o-아실옥심 유도체, 그의 제조방법 및 이를유효성분으로 하는 심장순환계 질환의 예방 및 치료용약학 조성물 |
| DE102004061006A1 (de) | 2004-12-18 | 2006-06-22 | Bayer Healthcare Ag | 3-Benzylthio-1,2,4-triazin-5(2H)-one |
| DE102004061009A1 (de) | 2004-12-18 | 2006-06-22 | Bayer Healthcare Ag | Substituierte 1,2,4-Triazin-5(2H)-one |
| DE102004061005A1 (de) | 2004-12-18 | 2006-06-22 | Bayer Healthcare Ag | 3-Cycloalkyl-1,2,4-triazin-5(2H)-one |
| DE102004061008A1 (de) | 2004-12-18 | 2006-06-22 | Bayer Healthcare Ag | 3-Arylalkyl- und 3-Heteroarylalkyl-substituierte 1,2,4-Triazin-5(2H)-one |
| US20060280748A1 (en) * | 2005-04-22 | 2006-12-14 | Buckheit Robert W Jr | Plasma or serum fraction for treatment or prevention of abnormal cell proliferation |
| AU2006242651B2 (en) * | 2005-04-29 | 2013-05-16 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
| WO2007029081A1 (en) * | 2005-09-05 | 2007-03-15 | Ranbaxy Laboratories Limited | Galantamine-containing controlled release oral dosage forms, processes for the preparation thereof and use for the manufacture of a medicament |
| WO2008048867A2 (en) * | 2006-10-13 | 2008-04-24 | Glaxo Group Limited | Bicyclic heteroaromatic compounds |
-
2007
- 2007-05-11 BR BRPI0721697-1A2A patent/BRPI0721697A2/pt not_active IP Right Cessation
- 2007-05-11 EP EP15163560.4A patent/EP2977452A3/en not_active Withdrawn
- 2007-05-11 EP EP07776985.9A patent/EP2152865B1/en not_active Not-in-force
- 2007-05-11 MX MX2009012188A patent/MX2009012188A/es active IP Right Grant
- 2007-05-11 CN CN2007800537081A patent/CN101986785A/zh active Pending
- 2007-05-11 EA EA200971050A patent/EA200971050A1/ru unknown
- 2007-05-11 AU AU2007353454A patent/AU2007353454C8/en not_active Ceased
- 2007-05-11 KR KR1020147010441A patent/KR101690390B1/ko not_active Expired - Fee Related
- 2007-05-11 JP JP2010507369A patent/JP5277243B2/ja not_active Expired - Fee Related
- 2007-05-11 KR KR1020097025806A patent/KR101461659B1/ko not_active Expired - Fee Related
- 2007-05-11 WO PCT/US2007/011365 patent/WO2008140449A1/en not_active Ceased
- 2007-05-11 KR KR1020157033416A patent/KR101730290B1/ko not_active Expired - Fee Related
- 2007-05-11 ES ES07776985.9T patent/ES2540933T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2007353454A1 (en) | 2008-11-20 |
| EP2152865B1 (en) | 2015-04-15 |
| AU2007353454B2 (en) | 2013-10-31 |
| EP2152865A1 (en) | 2010-02-17 |
| EP2152865A4 (en) | 2010-11-03 |
| AU2007353454C8 (en) | 2014-04-24 |
| EA200971050A1 (ru) | 2010-06-30 |
| KR20150138419A (ko) | 2015-12-09 |
| BRPI0721697A2 (pt) | 2014-08-05 |
| CN101986785A (zh) | 2011-03-16 |
| KR20100061616A (ko) | 2010-06-08 |
| JP2010526805A (ja) | 2010-08-05 |
| EP2977452A2 (en) | 2016-01-27 |
| KR20140052087A (ko) | 2014-05-02 |
| AU2007353454C1 (en) | 2014-03-27 |
| ES2540933T3 (es) | 2015-07-14 |
| KR101461659B1 (ko) | 2014-11-17 |
| KR101730290B1 (ko) | 2017-04-25 |
| WO2008140449A1 (en) | 2008-11-20 |
| KR101690390B1 (ko) | 2016-12-27 |
| EP2977452A3 (en) | 2016-05-25 |
| JP5277243B2 (ja) | 2013-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2977452A3 (en) | Methods of treatment and prevention of neurodegenerative diseases and disorders | |
| WO2006083533A3 (en) | Compositions and methods for inhibiting drusen formation and for diagnosing or treating drusen-related disorders | |
| TW200738724A (en) | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
| WO2009127642A3 (en) | Use of lrrk2 inhibitors for neurodegenerative diseases | |
| MX2010003667A (es) | Compuestos alcoxi para el tratamiento de enfermedades. | |
| GEP20084420B (en) | Use of imidazole compounds for the treatment of neurodegenerative disorders | |
| EA200901032A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| TN2010000122A1 (en) | Compounds and compositions as modulators of gpr119 activity | |
| MX2009009491A (es) | Compuestos y composiciones como moduladores de la actividad del gpr119. | |
| IN2012DN02469A (cg-RX-API-DMAC7.html) | ||
| WO2008021210A3 (en) | Methods and compositions for the treatment of neurodegenerative disorders | |
| MX2009010407A (es) | Derivados fluorados de deferiprona. | |
| MX2009005725A (es) | Metodos y composiciones para tratamiento y monitoreo de tratamiento de trastornos asociados con il-13. | |
| MY161818A (en) | Styrenyl derivate compounds for treating ophthalmic diseases and disorders | |
| WO2012040727A3 (en) | Methods for diagnosis and treatment of neurodegenerative diseases or disorders | |
| MX2010003269A (es) | Derivados de pirrolotriazina utiles para tratar cancer a traves de la inhibicion de la aurora quinasa. | |
| EP2416795A4 (en) | COGNITIVE DECLINE INHIBITORS | |
| WO2010075280A3 (en) | Coumarin-based compounds for the treatment of alzheimer's disease and cancer | |
| MX2010010303A (es) | Nuevos compuestos de acido ribonucleico de pequeña interferencia para inhibir rtp801. | |
| DE602006016449D1 (cg-RX-API-DMAC7.html) | ||
| WO2009123948A3 (en) | Compounds and compositions as itpkb inhibitors | |
| MX2018009662A (es) | Metodo y composicion farmaceutica para tratamiento de neurodegeneracion. | |
| EP2542085A4 (en) | COMPOUNDS FOR THE TREATMENT OF NEURODEEGENERATIVE DISORDER | |
| TW200628473A (en) | Novel heterocycles | |
| MX2009013482A (es) | Derivados de [1,10]-fenantrolina para el tratamiento de enfermedades neurodegenerativas o hematologicas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |